EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease

Nicholas A Iovino iD, Madeline G McClinchie, Mahmoud Abdel-Rasoul, Brendan Boyle, Jennifer L Dotson, Hilary K Michel, Ross M Maltz

Journal of Pediatric Gastroenterology and Nutrition · 2024

DOI: 10.1002/jpn3.12299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Nicholas A Iovino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Drug Therapy, Combination, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Crohn's and Colitis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Combination therapy consists of both anti‐tumor necrosis factor (anti‐TNF) and an immunomodulator (IMM) and has been shown to improve outcomes in patients with inflammatory bowel disease (IBD). This study assesses the impacts of IMM withdrawal from combination therapy to anti‐TNF monotherapy in children with IBD.

Methods

This single‐center retrospective cohort study included children with IBD initiated on combination therapy between 2014 and 2019 who discontinued the IMM. We evaluated whether IMM withdrawal impacts laboratory values and disease activity. Linear mixed effects models with random intercepts were used to compare differences between groups. Chi‐square and Kruskal–Wallis tests were used for comparisons between patients who did and did not require subsequent escalation of therapy.

Results

One hundred and fifty‐two patients discontinued the IMM which did not significantly affect disease activity. However, 18% of patients escalated therapy after IMM withdrawal, primarily due to low anti‐TNF levels. Lower anti‐TNF and higher erythrocyte sedimentation rate (ESR) and C‐reactive protein (CRP) levels before IMM withdrawal were associated with subsequent escalation of therapy. Overall, there was no statistically significant effect on anti‐TNF drug levels. Patients with Crohn's disease (CD) on infliximab (IFX) and methotrexate (MTX) who discontinued the IMM had an increase in mean ESR and CRP ( p < 0.05).

Conclusions

IMM withdrawal from anti‐TNF combination therapy may be considered safe in the setting of higher anti‐TNF levels and normal serum inflammatory markers. Clinicians should consider assessing anti‐TNF levels and inflammatory markers after IMM withdrawal, especially in patients with CD receiving IFX who discontinued MTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Therapy, CombinationTumor Necrosis Factor-alphaHumansRetrospective StudiesMaleFemaleChildAdolescentInflammatory Bowel DiseasesImmunomodulating AgentsCrohn DiseaseInfliximabImmunologic FactorsC-Reactive Protein

Stichwörter der Autor:innen

biologicde‐escalationmonotherapytherapeutics

Substanzen

Tumor Necrosis Factor-alphaImmunomodulating AgentsInfliximabImmunologic FactorsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Pediatrics, Columbus, Ohio, USA.
  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Center for Child Health Equity and Outcomes Research, The Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.

ORCID-Profile: Nicholas A Iovino

Förderung

  • Crohn's and Colitis Foundation

Zitieren

APA

Iovino, N. A., McClinchie, M. G., Abdel-Rasoul, M., Boyle, B., Dotson, J. L., Michel, H. K., & Maltz, R. M. (2024). Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12299

Vancouver

Iovino NA, McClinchie MG, Abdel-Rasoul M, Boyle B, Dotson JL, Michel HK, et al. Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12299

BibTeX
@article{Iovino2024,
  author = {Iovino, Nicholas A and McClinchie, Madeline G and Abdel-Rasoul, Mahmoud and Boyle, Brendan and Dotson, Jennifer L and Michel, Hilary K and Maltz, Ross M},
  title = {Clinical impacts of immunomodulator withdrawal from anti‐tumor necrosis factor combination therapy in pediatric inflammatory bowel disease},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  doi = {10.1002/jpn3.12299}
}
Kostenlos starten →